[go: up one dir, main page]

HK1042017A1 - 低腺苷反義寡核苷酸、組合物、試劑盒及與支氣管緊縮、肺炎、過敏及表面活性劑缺失相關的通氣途徑疾病的治療方法 - Google Patents

低腺苷反義寡核苷酸、組合物、試劑盒及與支氣管緊縮、肺炎、過敏及表面活性劑缺失相關的通氣途徑疾病的治療方法

Info

Publication number
HK1042017A1
HK1042017A1 HK02102615.9A HK02102615A HK1042017A1 HK 1042017 A1 HK1042017 A1 HK 1042017A1 HK 02102615 A HK02102615 A HK 02102615A HK 1042017 A1 HK1042017 A1 HK 1042017A1
Authority
HK
Hong Kong
Prior art keywords
bronchoconstriction
ies
allergy
kit
compositions
Prior art date
Application number
HK02102615.9A
Other languages
English (en)
Chinese (zh)
Inventor
喬納森‧W‧尼斯
Original Assignee
東卡羅來納大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 東卡羅來納大學 filed Critical 東卡羅來納大學
Publication of HK1042017A1 publication Critical patent/HK1042017A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK02102615.9A 1999-04-06 2002-04-08 低腺苷反義寡核苷酸、組合物、試劑盒及與支氣管緊縮、肺炎、過敏及表面活性劑缺失相關的通氣途徑疾病的治療方法 HK1042017A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12795899P 1999-04-06 1999-04-06
PCT/US2000/008020 WO2000062736A2 (fr) 1999-04-06 2000-03-24 Oligonucleotide antisens a faible teneur en adenosine, compositions, kit et procede pour le traitement d'affections des voies aeriennes associees a la bronchoconstriction, a l'inflammation pulmonaire, aux allergies et a la depletion de surfactant

Publications (1)

Publication Number Publication Date
HK1042017A1 true HK1042017A1 (zh) 2002-08-02

Family

ID=22432865

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102615.9A HK1042017A1 (zh) 1999-04-06 2002-04-08 低腺苷反義寡核苷酸、組合物、試劑盒及與支氣管緊縮、肺炎、過敏及表面活性劑缺失相關的通氣途徑疾病的治療方法

Country Status (9)

Country Link
EP (1) EP1168919A4 (fr)
JP (1) JP2003515525A (fr)
CN (1) CN1330513A (fr)
AU (1) AU4031700A (fr)
BR (1) BR0006019A (fr)
CA (1) CA2330022A1 (fr)
HK (1) HK1042017A1 (fr)
IL (1) IL140054A0 (fr)
WO (1) WO2000062736A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730477B1 (en) 1998-08-04 2004-05-04 Diadexus, Inc. Method of diagnosing, monitoring and staging breast cancer
US6737040B1 (en) 1998-08-04 2004-05-18 Diadexus, Inc. Method and antibody for imaging breast cancer
WO2000058468A2 (fr) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 47 proteines humaines secretees
DE10049549A1 (de) 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
AU2002319033B2 (en) 2001-07-06 2008-01-10 Pharmaxis Ltd Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
WO2004086052A2 (fr) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Produits de diagnostic et de therapeutique pour des maladies liees au recepteur de l'adenosine a2b couple a la proteine g (adora2b)
US7671182B2 (en) * 2003-03-31 2010-03-02 Council Of Scientific & Industrial Research Gene variants of signal transducer and activator of transcription-6 (STAT 6) variants and process of detection the same
KR101350837B1 (ko) * 2003-12-03 2014-01-14 코다 테라퓨틱스, 인크. 코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법
WO2006010492A1 (fr) * 2004-07-28 2006-02-02 Bayer Healthcare Ag Diagnostics et therapeutiques pour des maladies associees a tryptase 1 (tps1)
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US8673268B2 (en) 2004-10-15 2014-03-18 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2006086821A1 (fr) * 2004-10-20 2006-08-24 Antisense Therapeutics Ltd MODULATION ANTISENS DE L'EXPRESSION DE L'INTÉGRINE α4
ES2450929T3 (es) 2004-10-29 2014-03-25 Topigen Pharmaceuticals Inc. Oligonucleótidos antisentido para tratar la alergia y la proliferación de las células neoplásicas
AU2005307831A1 (en) 2004-11-17 2006-05-26 Amgen, Inc. Fully human monoclonal antibodies to IL-13
EP1877557A2 (fr) 2005-04-04 2008-01-16 The Board of Regents of The University of Texas System Microarn regulant des cellules musculaires
PL2068889T3 (pl) 2006-08-10 2020-06-29 Roy C. Levitt Anakinra do zastosowania do leczenia zespołu zarostowego zapalenia oskrzelików
WO2010111503A2 (fr) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Inhibition à médiation par l'interférence arn de l'expression du gène de la chaîne alpha du récepteur à haute affinité pour les ige (fcεr1α) faisant appel à de courts acides nucléiques interférents (ansi)
PL3327141T3 (pl) * 2013-04-19 2020-07-27 Epiontis Gmbh Sposób określania ilościowego składu komórkowego w próbce biologicznej
CN112969799A (zh) * 2018-09-26 2021-06-15 奥姆生命科技公司 2′fana修饰的foxp3反义寡核苷酸及其使用方法
CN109260217A (zh) * 2018-09-30 2019-01-25 深圳松乐生物科技有限公司 3`-脱氧次黄嘌呤核苷在制备用于多种疾病药品、食品或保健品中的应用
CN114591963B (zh) * 2022-05-10 2022-07-19 上海优替济生生物医药有限公司 sgRNA及利用其构建GM-CSF(-)细胞的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE637965T1 (de) * 1991-11-26 1995-12-14 Gilead Sciences Inc Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen.
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5320962A (en) * 1992-07-22 1994-06-14 Duke University DNA encoding the human A1 adenosine receptor
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
CN1202900A (zh) * 1995-11-21 1998-12-23 Icn药品公司 用il－8和il－8受体的反义寡核苷酸抑制肿瘤生长
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
ATE353657T1 (de) * 1997-09-05 2007-03-15 Univ California Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
AU757894B2 (en) * 1998-05-21 2003-03-13 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids
CN1317009A (zh) * 1998-08-03 2001-10-10 东卡罗来纳大学 低腺苷反义寡核苷酸制剂、组合物、试剂盒及处理

Also Published As

Publication number Publication date
IL140054A0 (en) 2002-02-10
CN1330513A (zh) 2002-01-09
AU4031700A (en) 2000-11-02
WO2000062736A2 (fr) 2000-10-26
EP1168919A4 (fr) 2002-03-06
BR0006019A (pt) 2001-03-13
WO2000062736A3 (fr) 2001-10-11
CA2330022A1 (fr) 2000-10-26
EP1168919A2 (fr) 2002-01-09
JP2003515525A (ja) 2003-05-07

Similar Documents

Publication Publication Date Title
IL140054A0 (en) Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion
EP1222309A4 (fr) Rnase h humaine et compositions nucleotidiques correspondantes
PL342062A1 (en) Method of treating sexual disorders among women
HK1103631A1 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
HK1042706A1 (zh) 低腺苷反義寡核苷酸製劑、組合物、試劑盒及處理
AU2002305236A8 (en) Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
HK1062170A1 (en) Process for the preparation of 1,3-substituted in denes and aryl-fused azapolycyclic compounds
ZA991053B (en) Method and composition for treatment of inflammatory conditions.
HK1041880A1 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders.
ZA200105293B (en) Use of growth hormone secretagogues for treatment of physical performance decline.
IL155433A0 (en) Treatment of t cell disorders
EP1051169A4 (fr) Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU6082101A (en) Nucleotide sequences involved in increasing or decreasing mammalian ovulation rate
EP1079764A4 (fr) Traitement des troubles de la sexualite chez certains groupes de patients
ZA200203435B (en) Method and compositions for treating pulmonary diseases.
AU2002348299A8 (en) Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
ZA200105259B (en) Use of growth hormone secretagogues for stimulating or increasing appetite.
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AU2001238288A1 (en) Method and compositions for treating fibrotic diseases
AU2001231987A1 (en) Polyanionic polyglycosides in the treatment of autism
HUP0200466A3 (en) Lipoglycan compositions and methods of treating parasitic infections
HUP0300043A3 (en) Method and composition for the treatment of pain
AU2002246307A1 (en) Polyherbal composition for the treatment of bronchial asthma and the process
AU2003258177A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases